Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease

Mario Cazzola, Clive Page, Luigino Calzetta, Maria Gabriella Matera

Research output: Contribution to journalArticlepeer-review

13 Citations (Scopus)

Abstract

Ensifentrine (RPL554), an inhaled 'bifunctional' dual phosphodiesterase 3/4 inhibitor that exhibits both bronchodilator and anti-inflammatory activities, provides a new option in the treatment of chronic obstructive pulmonary disease (COPD) and other inflammatory airway diseases that are under clinical development. Ensifentrine appears to be initially under development for the treatment of COPD although it is not yet clear whether it should be understood as an add-on therapy in patients for the treatment of acute exacerbations of COPD or for the regular maintenance treatment of patients either alone, or on top of existing drug classes.

Original languageEnglish
Pages (from-to)249-257
Number of pages9
JournalPharmaceutical patent analyst
Volume7
Issue number6
DOIs
Publication statusPublished - 18 Jan 2019

Keywords

  • asthma
  • COPD
  • cystic fibrosis
  • ensifentrine
  • mixed phosphodiesterase (PDE)3/4 inhibitor
  • PDE isoenzymes

Fingerprint

Dive into the research topics of 'Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease'. Together they form a unique fingerprint.

Cite this